| OSI Pharmaceuticals announced that the Oncologic Drugs Advisory Committee) will review the use of Tarceva as a first-line maintenance therapy for patients with advanced non-small cell lung cancer who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16, 2009 meeting. The ODAC panel is a committee of external experts, formed by the U.S. Food and Drug Administration, to advise the FDA in the evaluation of marketed and investigational drugs for use in the treatment of cancer. :theflyonthewall.com |
Subscribe for More Information